文献速递肺外科

非典型肺类癌外科治疗的全国性研究

A National Study of Surgically Managed Atypical Pulmonary Carcinoid Tumors.
PubMed 文献 · Ann Thorac Surg · 2020-11-04

基于美国国家癌症数据库2010至2015年数据,比较816例非典型与5688例典型肺类癌患者。非典型类癌患者年龄更大、肿瘤更大、分期更晚,I至IV期未调整5年总生存率分别为84%、74%、52%和51%。淋巴结升级在非典型类癌中占16%,典型类癌中占7%。手术切除范围(肺叶切除对比亚肺叶切除)未被识别为非典型类癌的生存预测因素。

要点

  • 非典型肺类癌I至IV期未调整5年总生存率分别为84%、74%、52%和51%。
  • 非典型类癌淋巴结升级率为16%,典型类癌为7%。
  • 手术切除范围(肺叶对比亚肺叶)未显示为非典型类癌生存预测因素。

核心结论

  • 非典型肺类癌是类癌的独特亚群,倾向于更具侵袭性行为,需进一步研究最佳手术管理。

研究设计与样本

  • 回顾性队列研究,纳入美国国家癌症数据库2010至2015年18岁及以上诊断为非典型或典型肺类癌的患者,共816例非典型和5688例典型类癌。
  • 生存分析采用Kaplan-Meier法和多变量Cox比例风险回归,调整患者和肿瘤特征。

主要发现

  • 非典型类癌患者倾向于年龄更大、肿瘤更大、分期更晚。
  • 非典型类癌未调整5年总生存率:I期84%、II期74%、III期52%、IV期51%。
  • 典型类癌未调整5年总生存率:I期93%、II期93%、III期89%、IV期87%。
  • 淋巴结升级(临床N0患者手术标本中发现淋巴结转移)见于16%非典型和7%典型类癌患者。
  • 多变量分析中,年龄增加、合并症和分期是非典型类癌患者死亡的显著预测因素。

临床怎么用

  • 非典型肺类癌分期越晚生存率越低,应重视准确分期和淋巴结评估。
  • 肺叶切除与亚肺叶切除在非典型类癌中未显示生存差异,术式选择需个体化。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atypical pulmonary carcinoid tumors represent a subset of non-small cell lung cancer; however, their relative infrequency has left prognosis, management and long-term survival associated with atypical carcinoids, incompletely characterized. METHODS: Patients aged 18 years or more diagnosed with atypical or typical pulmonary carcinoid between 2010 and 2015 within the National Cancer Database were evaluated. Survival was measured using Kaplan-Meier survival and multivariable Cox proportional hazards regression, adjusting for patient and tumor attributes. RESULTS: A total of 816 atypical and 5688 typical carcinoid patients were identified in the cohort. Patients with atypical carcinoids tended to be older, have larger tumors, and later stage disease. The unadjusted overall 5-year survival for atypical carcinoid patients was 84%, 74%, 52%, and 51% for stages I, II, III, and IV, respectively. The unadjusted 5-year survival for typical carcinoids was 93%, 93%, 89%, and 87% for stages I, II, III, and IV, respectively. Nodal upstaging (ie, lymph node metastases identified in surgical specimens of clinically staged N0 patients) was seen in 16% of atypical and 7% of typical carcinoid patients. Increasing age, comorbidities, and stage were identified as significant predictors of mortality for atypical patients in multivariable analysis. Extent of surgical resection (lobectomy vs sublobar) was not identified as a predictor of survival for atypical carcinoid. CONCLUSIONS: Atypical carcinoid tumors represent a distinct subset of carcinoid tumors, with a tendency toward more aggressive behavior. Further study of the optimal surgical management is warranted.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Walters SL, Canavan ME, Salazar MC, et al. A National Study of Surgically Managed Atypical Pulmonary Carcinoid Tumors. Ann Thorac Surg. 2020. PMID: 33159862. doi:10.1016/j.athoracsur.2020.09.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。